Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PEAR
- 16 Jun 2016 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 16 Jun 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 16 Jun 2016 Status changed from not yet recruiting to recruiting.